Maha Shakir Hasan1, Husam Mohammed Kredy2*, Hadeel Rashid Faraj2
الملخص الانجليزي
Objective: Breast cancer is the most common cancer among women, comprising 18% of all female cancers,
and worldwide, breast cancer is the fifth most common cause of cancer mortality. The study was designed
to determine and compare the levels of phospholipase D1 (PLD1) and choline kinase alpha (CHKAα)
enzymes in Breast cancer patients and apparently healthy individuals. Material and Methods: Blood
phospholipase D1 (PLD1) and choline kinase alpha (CHKAα) enzymes levels were determined in 85
breast cancer patients and 55 apparently healthy subjects. Histopathological and immunohistochemical
analysis done for (50) cases (out of those 85 breast cancer patients), tissue samples are collected from
patients with breast cancer who undergoing surgical resection (mastectomy) and normal breast tissues:
(control group, which include normal breast tissue from patients with benign lesions, and normal breast
tissue from the same women with breast cancer). Results: The levels of serum phospholipase D1 (PLD1)
and choline kinase alpha (CHKAα) enzymes were showing significant increase in breast cancer patients
as compared to control group (P ≤ 0.05). We found that 82% of breast cancer biopsies were phospholipase
D1 positive. There was no expression of phospholipase D1 in all normal breast tissues. Sixty-seven
percent of breast cancer biopsies were choline kinase alpha positive. There was no expression of choline
kinase alpha in all normal breast tissues. Conclusion: In Breast cancer patients, we found that there is
an increase in (PLD1) and (CHKAα) enzymes level both in serum and malignant tissue, and this
suggests that the overexpression of PLD1 and CHKAα may play an important role in the human breast
tumorigenesis and they are useful markers for breast cancer.